As of June 6, 2025, Forward Pharma A/S (FWP) reports a ROA (Return on Assets) of -2.65%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Forward Pharma A/S's ROA (Return on Assets)
Over recent years, Forward Pharma A/S's ROA (Return on Assets) has shown a stable trend. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2021-12-31 | -2.65% |
| 2020-12-31 | -8.03% |
| 2019-12-31 | -5.37% |
| 2018-12-31 | -10.44% |
| 2017-12-31 | 826.22% |
This slight upward trend highlights how Forward Pharma A/S manages its efficiency in using assets to generate earnings over time.
Comparing Forward Pharma A/S's ROA (Return on Assets) to Peers
To better understand Forward Pharma A/S's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Forward Pharma A/S (FWP) | -2.65% |
| Saniona AB (SANION.ST) | 55.55% |
| Genmab A/S (GMAB.CO) | 17.12% |
| Bavarian Nordic A/S (BAVA.CO) | 6.86% |
| PharmaCyte Biotech Inc (PMCB) | 0.56% |
| Zealand Pharma A/S (ZEAL.CO) | -11.35% |
Compared to its competitors, Forward Pharma A/S's ROA (Return on Assets) is among the highest compared to peers, demonstrating superior efficiency in generating earnings from assets.